Skoči na glavni sadržaj

Pregledni rad

Anemia in chronic kidney disease

Kristijan Mužić orcid id orcid.org/0000-0002-3598-8819 ; Dom zdravlja Primorsko-goranske županije, Ispostava “Dr. Dinko Kozulić”, Mali Lošinj
Sanjin Rački ; Zavod za nefrologiju i dijalizu, Klinika za internu medicinu, Klinički bolnički centar Rijeka


Puni tekst: hrvatski pdf 292 Kb

str. 471-481

preuzimanja: 5.150

citiraj


Sažetak

Renal anemia is the result of chronic kidney disease (CKD) and deteriorates with
disease progression. If there is no proteinuria, anemia may be the first sign of kidney disease.
In all patients with anemia and CKD diagnostic evaluation is required. Prior to diagnose
a renal anemia, it is neccesary to eliminate possible other causes. A direct correlation
between the concentration of hemoglobin and stage of renal failure is well known. Early
anemia is common in diabetic patients. The correction of anemia may slow the progression
of CKD. Anemia is an independent risk factor for developing cardiovascular disease in patients
with CKD. It is associated with left ventricular hypertrophy and congestive heart failure
in patients with or without kidney disease. In some patients correction may slow the
deterioration of cardiac function and has been proven to amelliorate the existing damage.
Anemia is the result of chronic heart failure and chronic renal failure. It is also a condition
that worsens function of both organic systems and makes the vicious triangle called “cardiorenal
anemia syndrome”. Decreased concentration of hemoglobin in diabetic patients is an
independent risk factor for cardiovascular complications and may adversely affect the
chronic complications of diabetes. Recent publications suggest that targeting to the higher
value of hemoglobin is controversial, because it can lead to an increased risk of serious cardiovascular
events. It is still unclear whether different effects of anemia correction are the
result of hemoglobin values which are achieved or whether erythropoiesis stimulating
agents cause numerous pleotropic events. Treatment of the anemia in patients with chronic
kidney disease is based on the current guidelines.

Ključne riječi

anemia; cardiovascular disease; chronic kidney disease; erythropoiesis stimulating agent

Hrčak ID:

63070

URI

https://hrcak.srce.hr/63070

Datum izdavanja:

8.12.2010.

Podaci na drugim jezicima: hrvatski

Posjeta: 6.610 *